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Research
Before the 1970s, polychlorinated biphenyls
(PCBs) had been used rather extensively in
industries involving the manufacture of trans-
formers, capacitors, and noncarbon copying
papers. Despite the subsequent banning of
PCBs because of their chemical stability and
lipophilicity, PCBs continued to be an envi-
ronmental and human health concern through
bioaccumulation and biomagnification.
Because humans are at the top of the food
chain, it is not surprising that PCBs are consis-
tently found in a variety of human tissues.
One of the most serious human health
concerns from environmental contamination
of PCBs is their presence in breast milk.
Indeed, PCBs have been detected in milk sam-
ples from lactating mothers in the United
States (Greizerstein et al. 1999; Schecter et al.
1998), Japan (Inoue et al. 2006; Suzuki et al.
2005), Spain (Angulo et al. 1999; Ramos et al.
1997), Taiwan (Wang SL, Chen JW, unpub-
lished data), and all over the world (Dewailly
et al. 1996; Glynn et al. 2001; Polder et al.
2003; Vartiainen et al. 1997). This is a serious
human health concern because milk, with its
high lipid content, represents a concentrated
delivery mechanism of PCBs to infants.
Furthermore, a number of human epidemio-
logic and animal experimental studies have
established an association between neuro-
developmental and neurobehavioral deficits
and PCB exposure (Huisman et al. 1995;
Jacobson et al. 1990; Tilson et al. 1990). At
the cellular and molecular levels, exposure to
PCBs during the developmental stage is
known to disrupt thyroid hormone homeo-
stasis and dopamine levels in the brain (Goldey
et al. 1995; Seegal et al. 1997).
Given the human biomonitoring levels in
breast milk worldwide, how can we effec-
tively use such information? In this article,
we present an approach to render such
human biomonitoring results useful by using
physiologically based pharmacokinetic
(PBPK) modeling. We first transformed an
earlier PBPK model for lactational transfer of
PCB-153 in mice (Lee et al. 2007) into a
PBPK model for a nonpregnant human
female at an average childbearing age of
25 years. We focused on PCB-153 because it
is the most prevalent PCB congener detected
in human tissue, often representing around
27–30% of the total detected PCB congeners
in human tissues (Inoue et al. 2006; Kiviranta
et al. 2005). We then predicted the body
burden buildup of PCB-153 from birth over
a 25-year period based on realistic exposure
levels found in foods, as reported for the
Japanese population (Akutsu et al. 2005). In
doing so, we incorporated all age-related
physiologic changes during the first 25-year
life span of a human female. Next, we trans-
formed the PBPK model to a lactating
25-year-old woman by incorporating all the
physiologic changes related to pregnancy and
childbirth. Using this model, we predicted
milk levels of PCB-153 using three sets of
values (minimal, median, maximal) for the
most sensitive parameters based on actual
data reported in the literature. We found
model predictions of PCB-153 in breast milk
to bracket the human biomonitoring data
found worldwide. We addressed uncertainties
and variability through the modeling but did
not conduct parameter estimation. Using this
PBPK model, we carried out reverse dosime-
try simulation to suggest possible exposure
scenarios leading to the breast milk concen-
trations of PCB-153 in Canadian Inuits
being the highest in the world.
Materials and Methods
PBPK model development. We developed a
PBPK model to predict the concentration of
PCB-153 in human milk. Our model was
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BACKGROUND: One of the most serious human health concerns related to environmental contami-
nation with polychlorinated biphenyls (PCBs) is the presence of these chemicals in breast milk. 
OBJECTIVES: We developed a physiologically based pharmacokinetic model of PCB-153 in women,
and predict its transfer via lactation to infants. The model is the ﬁrst human, population-scale lacta-
tional model for PCB-153. Data in the literature provided estimates for model development and
for performance assessment. 
METHODS: We used physiologic parameters from a cohort in Taiwan and reference values given in
the literature to estimate partition coefﬁcients based on chemical structure and the lipid content in
various body tissues. Using exposure data from Japan, we predicted acquired body burden of
PCB-153 at an average childbearing age of 25 years and compared predictions to measurements
from studies in multiple countries. We attempted one example of reverse dosimetry modeling using
our PBPK model for possible exposure scenarios in Canadian Inuits, the population with the highest
breast milk PCB-153 level in the world.
RESULTS: Forward-model predictions agree well with human biomonitoring measurements, as
represented by summary statistics and uncertainty estimates. 
CONCLUSION: The model successfully describes the range of possible PCB-153 dispositions in
maternal milk, suggesting a promising option for back-estimating doses for various populations.
KEY WORDS: body burden, exposure reconstruction, human milk biomonitoring, lactational trans-
fer, PCB-153, physiologically based pharmacokinetic modeling, polychlorinated biphenyls, reverse
dosimetry. Environ Health Perspect 116:1629–1634 (2008). doi:10.1289/ehp.11519 available via
http://dx.doi.org/ [Online 24 July 2008]derived from a model for PCB-153 transfer in
pregnant and lactating mice (Lee et al. 2007).
We limited the complexity of the human
PBPK model to a five-compartment model
consisting of four well-mixed tissue groups—
liver, fat, mammary tissue, and rest of the
body—and a mixed blood compartment
(Figure 1), because available human data did
not justify a more reﬁned model, nor was one
needed for our population-scale, multiyear
model assessments/predictions.
All tissues in the model are ﬂow-limited.
PCB-153 is input directly into the liver, where
metabolism occurs with a ﬁrst-order metabolic
coefﬁcient allometrically extrapolated from the
mouse value reported by Lee et al. (2007). We
used postdelivery body weight measured at
Taizhong hospital in Taiwan; this study also
involved determining PCB concentration in
milk, cord blood, and maternal venous blood.
We modeled postpartum weight loss via for-
mulas from Haiek et al. (2001). We used
physiologic parameters for nursing women
from Gentry et al. (2003), Fisher et al. (1997),
and Byczkowski and Fisher (1995) (Tables 1
and 2).
Akutsu et al. (2005) reported daily intakes
of PCB-153 in Japan of 0.00125–0.13
µg/kg/hr (median, 0.0068 µg/kg/hr). De Amici
et al. (2001) and Fisher et al. (1997) reported
milk production rates between 0.0033 and
0.06 L/hr (median, 0.0317 L/hr). We simu-
lated population-scale exposure by uniformly
sampling from this range of intakes and milk
production rates.
To facilitate the data and statistical analy-
ses, we coded our ﬁnal model using R statisti-
cal software, version 2.7.2 (R Foundation for
Statistical Computing 2008), an integrated
suite of software facilities for data manipula-
tion, calculation, and graphical display.
Calculation of partition coefficients. We
calculated partition coefﬁcients (Table 1) using
methods from Parham et al. (1997), who
described calculations to determine the adi-
pose:plasma and adipose:blood coefﬁcients for
any PCB using the structural properties of that
PCB. Coefﬁcients for other tissues were deter-
mined by multiplying the adipose:blood coefﬁ-
cient by an adjustment factor related to the
lipid composition of the target tissue. We used
adjustment factors, deﬁned as 
LTotTissue × Fraction of lipid for that tissue 
÷ LTotFat × Fraction of lipid for fat, 
where LTot = fraction of neutral lipids + 0.3 ×
fraction of nonneutral lipids in a tissue, as
described by Parham et al. (1997), or calcu-
lated from DeJongh et al. (1997). We exam-
ined the lipid fractions of tissues from a
number of sources in the literature, and they
were very similar. We do not believe that the
minor differences of those published results
would signiﬁcantly inﬂuence the outcome of
our PBPK modeling. Thus, we chose to use
the values given by Parham et al. (1997) and
DeJongh et al. (1997). The partition coeffi-
cient for the body compartment was the aver-
age of the partition coefﬁcients for brain, skin,
and muscle. We obtained the distribution of
lipids of mammary tissue from Sakai et al.
(1992). We then calculated the adjustment
factor for mammary tissue.
Model simulations to build up body burden
through different developmental stages and to
incorporate physiologic changes of lactating
women. We simulated individuals beginning at
age 0. Body weight, blood volume, fat volume,
and cardiac output were evaluated according to
developmental stages by age group (0–1 year,
1–5 years, 5–10 years, 10–15 years, and
> 15 years) using values reported by Haddad
et al. (2001) and Price et al. (2003). We
assigned mammary tissue volume a very low
estimated value for ages < 13 years (an average
value for the onset of puberty) and its final
Redding et al.
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Figure 1. Five-compartment model of PCB-153
transfer during lactation.
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Table 1. Parameters used for lactating mothers.
Parameter Value Source/reference
Physiologic values
BW (kg) 63.9 (adjusted)a Taizhong hospital, present study
BH (cm) 167 Taizhong hospital, present study
Cardiac output fraction 18.0 Byczkowski and Fisher 1995
Blood volume (35.5 ×BH + 2.278 ×BW – 3,382) Price et al. 2003
×0.001/0.6178
Tissue volume (% of BW)
VLC 0.04 Byczkowski and Fisher 1995
VFC 0.22 Byczkowski and Fisher 1995
VMtC 0.025 Gentry et al. 2003
VRC 0.91b – (VLC + VFC + VMtC)
Blood ﬂow (% of cardiac output)
QLC 0.25 Byczkowski and Fisher 1995
QFC 0.1 Fisher et al. 1997
QMtC 0.07 Fisher et al. 1997
QRC 1 – (QLC + QFC + QMtC)
Milk volume (L) Adjustedc Kent et al. 1999
Milk production rate (L/hr) 0.0328 Kent et al. 2006
PCB-153 metabolic rate (L/hr) 0.000164 Extrapolated from mouse value
Partition coefﬁcients
Fat 303 Calculated from Parham et al. 1997
Mammary tissue 302 Calculated from Parham et al. 1997
Liver 17.9 Calculated from Parham et al. 1997
Body (average of partition coefﬁcients 16.3 Calculated from Parham et al. 1997
for brain, muscle, and skin)
Abbreviations: BH, body height; BW, body weight; QFC, fat blood ﬂow; QLC, liver blood ﬂow; QMtC, mammary tissue blood
ﬂow; QRC, body blood ﬂow; VFC, fat tissue volume; VLC, liver tissue volume; VMtC, mammary tissue volume; VRC, body tissue
volume.
aAdjusted according to the average of 20 subjects in a Taiwanese hospital. bThe value of 0.91 was used instead of 1 to take
into account parts of the body not included in the model, such as skeleton and hair. cMilk volume is a time-dependent func-
tion based on data from Kent et al. (1999). Details of the model code are available from the corresponding author on request.
Table 2. Parameters used for females 0–25 years
of age.
Parameter Value Reference
Body weight (kg)
0–1 year 9.8 Haddad et al. (2001)
1–5 years 18.8 Haddad et al. (2001)
5–10 years 31.9 Haddad et al. (2001)
10–15 years 51.5 Haddad et al. (2001)
> 15 years 54.4 Haddad et al. (2001)
Blood volume (L)
0–1 year 0.3 Haddad et al. (2001)
1–5 years 1.33 Haddad et al. (2001)
5–10 years 2.49 Haddad et al. (2001)
10–15 years 3.0 Present study 
> 15 years 4.2 Haddad et al. (2001)
Cardiac output (L/hr)
0–1 year 84 Price et al. (2003)
1–5 years 318.6 Price et al. (2003)
5–12 years 310.8 Price et al. (2003)
12–21 years 385.2 Price et al. (2003)
> 21 years 439.8 Price et al. (2003)
Fat volume fractiona
0–1 year 0.22 Haddad et al. (2001)
1–5 years 0.157 Haddad et al. (2001)
5–10 years 0.198 Haddad et al. (2001)
10–25 years 0.33 Haddad et al. (2001)
Mammary tissue volume
0–13 years 0.0001 Present study 
> 13 years 0.02 Gentry et al. (2003)
All other parameters and partition coefficients are the
same as those listed in Table 1.
aObtained by dividing adipose tissue weight by age-
appropriate body weight.lactational value at ages > 13 years. We
assumed an average childbearing age of
25 years, and thus, in the simulations, lacta-
tion is assumed to begin at this age.
The exposure input derived for PBPK
modeling of a 25-year-old woman through-
out her life is shown in Figure 2. Akutsu
et al. (2005) reported that the exposure of
Japanese to PCBs was in the range of
0.7–4.4 µg/person/day; the dominant con-
gener found was PCB-153, which accounted
for 9–15% of total PCBs. Thus, we derived
an estimation of 0.063–0.66 µg/person/day
exposure of PCB-153 in humans, as shown
in Figure 2. We assumed further that this
daily dose is divided evenly among three meals
and that each meal takes 15 min (0.25 hr) to
consume. Taking into consideration the aver-
age body weight of a 25-year-old woman to be
63 kg, we finally derived the body-
weight–dependent intake rate of PCB-153 to
be 0.00125–0.013 µg/kg body weight/hr
(Figure 2).
We addressed uncertainties and variability
in our PBPK model for lactational transfer of
PCB-153 in women by propagating such
uncertainties and variability in the inputs in
the model using Latin Hypercube sampling;
this eventually led to a much more robust
probability distribution for the population
PBPK modeling of milk contents of PCB-153
in lactating women. In the model, we per-
formed no parameter estimation to data com-
parisons shown in Figures 3–5. Our focus in
this work was to observe and comment on the
fidelity of a population-scale forward model
derived from independent sources of informa-
tion compared with worldwide measurements
of PCB-153.
Results
PBPK model simulations of PCB-153 con-
tents in serum, plasma, whole blood, and
milk compared with worldwide human bio-
monitoring data. Blood and tissue concentra-
tions for a 25-year-old woman generated by
this model were within ranges found in the
literature. Initial sensitivity analyses indicated
that milk production rate and initial fat con-
tent of PCB-153 were sensitive parameters for
milk concentration of PCB-153. When we
used the minimal, median, and maximal val-
ues of these sensitive parameters for model
simulation, as well as daily intake values
reported in the literature, the resulting three
curves encompassed the human milk moni-
toring data published by various investigators
(Angulo et al. 1999; Dewailly et al. 1996;
Glynn et al. 2001; Greizerstein et al. 1999;
Inoue et al. 2006; Polder et al. 2003; Ramos
et al. 1997; Schecter et al. 1998; Suzuki et al.
2005; Vartiainen et al. 1997). The ﬁnal simu-
lation results for PCB-153 concentration in
milk over a lengthy period of exposure were
indistinguishable if the exposure mode was
assumed to be via three meals daily or via a
constant infusion, as long as the daily input
was the same. Figure 3 shows an example of
1 of the 1,000 individuals simulated. The
apparent jaggedness in the curves resulted
from our rescaling of body parameters by
body weight at the above-mentioned times
and when mammary tissue develops. Figure 4
shows adult blood PCB-153 concentrations
in various geographic locations in the world
compared with simulation values.
Figure 5 shows a histogram of PCB-153
predicted in breast milk compared with global
Human PBPK model for lactational transfer of PCB-153
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Figure 2. Derivation of input exposure dose for PBPK modeling of loading body burden of PCB-153 in a
25-year-old woman. BW, body weight.
Estimated daily intake of total PCBs (sum of triCBs to heptaCBs)
in Japan, 0.7–4.4 μg/person/day. PCB-153 accounted
for 9–15% of total PCBs (Akutsu et al. 2005)
PCB-153 range of 0.063 μg/day (9% of 0.7 μg) to 0.66 μg/day (15% of 4.4 μg)
Intake of PCB-153 per meal of 0.021–0.22 μg
Intake rate (assuming meal lasts 0.25 hr), 0.084–0.88 μg/hr
÷ 3 (three meals per day)
÷ 3 BW (63 kg)
× 4 [transform meal time (0.25 hr to hourly rate)]
Body weight–dependent intake rate, 0.00125–0.013 μg/kg BW/hr
Figure 3. PCB-153 body-burden predictions for 1 of the 1,000 model simulations. In this model, we assumed
that mammary tissue develops at 13 years of age and that lactation begins at age 25. 
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Simulation results cmeasurements reported in the literature. The
range and spread in the model simulations,
caused by uncertainty only in intake and lacta-
tion rate, span the range in the measurements.
The mean model prediction also appears to be
quite close to many of the means reported in
the literature.
Reverse dosimetry modeling. Another appli-
cation of a PBPK model is to reconstruct a
possible exposure scenario from a given tissue
level of PCB-153. By varying or sliding the
intake dose, or other relevant physiologic para-
meters, we can obtain the PCB-153 milk con-
centration of interest. For example, Dewailly
et al. (1994) found a group of Canadian Inuits
to have a particularly high level of milk
PCB-153 (16.59 µg/L). In fact, the milk con-
tent of PCB-153 among these Canadian Inuits
is among the highest in the world (Figure 5).
Similarly, the serum PCB-153 concentration
of a group of ﬁshermen from the same region
is 2,457 ng/g lipid (Dewailly et al. 1994), or
14.7 µg/L in blood if we assume that blood is
0.6% lipid (Sakai et al. 1992). We raised the
oral intake dose of PCB-153 of the model
until we obtained mean milk levels of
PCB-153 close to those reported by Dewailly
et al. (1994) (Figure 6). More sophisticated
approaches to exposure reconstruction are
available (see, for example, Allen et al. 2007;
Sohn et al. 2004) but were not needed for this
work and are beyond the scope of this article.
We were able to postulate an estimate of the
daily intake dose of PCB-153 in this particular
population: an intake rate of 0.294 µg/hr/kg
body weight yielded a mean PCB-153 milk
concentration of 16.18 µg/L. Because all other
factors were held constant, the postulated dose
is a rough estimate. However, this intake rate
generates milk levels similar to those reported
for populations in this region of Canada
(Dewailly et al. 1994). 
Discussion
Based on actual human exposure data and
parameter values reported in the literature, our
PBPK model generates a range of results that
encompasses human biomonitoring data of
milk content of PCB-153 from all over the
world. Therefore, the model has good predic-
tive capability. Human biomonitoring data are
increasingly being collected in the United
States, Canada, and other countries in large-
scale ﬁeld studies. These studies are modeled
after the efforts of the U.S. Centers for Disease
Control and Prevention (CDC), which
released its Third National Report on Human
Exposure to Environmental Chemicals in the
summer of 2005 (CDC 2005). This report,
similar to its two predecessors but with
expanded effort, contains biomonitoring data
for the U.S. population for 148 environmental
chemicals, grouped into 14 classes, over the
period 2001–2002. Because so many chemicals
are detected in the human body at very low
levels, it is interesting to examine the health
signiﬁcance of these chemicals and ask what we
can do about these data. The application of
PBPK modeling and reverse dosimetry model-
ing in the present study may offer a glimpse
of the utility of human biomonitoring data
collected by the CDC and others.
In this model, we incorporated parameters
and exposure scenarios that were as realistic as
possible. Although we simplified our model
from the mouse model (Lee et al. 2007), we
maintained the most relevant compartments
(fat, mammary tissue for lactation, liver for
metabolism). We allometrically scaled the
ﬁrst-order rate constant for PCB-153 metabo-
lism from the mouse value given by Lee et al.
(2007) because we found no literature values
for PCB-153 metabolism in humans. We
divided the oral dose of PCB-153, given as a
single daily dose in the literature (Akutsu et al.
2005), into three meals to more accurately
represent intake. We have done simulations
with an exposure scenario of constant infusion
of the same daily dose over 24 hr, and the
results were not different from the scenario of
three meals per day.
We used appropriate age-dependent physi-
ologic values (body weight, blood volume, fat
volume, mammary tissue volume, and cardiac
output) to simulate the period during which
body burden of PCB-153 was acquired. Time
intervals of 5 years were chosen as small
enough to convey the changes brought on by
growth but large enough to obtain literature-
based values. The exception was mammary tis-
sue volume and growth, for which no accurate
values could be found in the literature. We
assigned mammary tissue volume pre- and
postpuberty values, with postpuberty values
given those of a lactating woman. This para-
meter is probably subject to a certain inaccu-
racy because it is unlikely that upon puberty
women acquire a mammary tissue volume
equal to that observed during lactation. We
did not model pregnancy separately.
In this model, we considered lactation to
be a uniform phenomenon for simplicity. Even
though the literature suggests that milk pro-
duction and content vary throughout the day,
as well as throughout lactation (Mitoulas et al.
2002), for the purposes of a PBPK model we
assumed that lactational performance was con-
stant, even over a wide range of maternal states
(Butte et al. 1984). Most PBPK lactational
models make similar assumptions with regard
to the modeling of lactation (Fisher et al. 1997;
Gentry et al. 2003; Lee et al. 2007).
Redding et al.
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Figure 5. Histogram of model simulations (right) compared with global measurements of PCB-153 in breast
milk (left). The uncertainty in the model predictions results from uncertainty in the daily PCB-153 intake
and in milk lactation rate. The blue circle in the model simulation bar chart indicates the mean prediction.
Data from Abraham et al. (1998), Germany; Angulo et al. (1999), Spain; Dewailly et al. (1994), Canadian
Inuits; Glynn et al. (2001), Norway; Greizerstein et al. (1999), Canada A and B, Mohawk, Quebec, New York
A and B, Netherlands A and B, Lithuania, France, Norway B, Germany A and B; Inoue et al. (2006), Japan;
Jaraczewska et al. (2006), Poland; Patterson et al. (1994), Sweden; Polder et al. (2003), Russia; Vartiainen
et al. (1997), Finland; and Wittsiepe et al. (2007), Germany C.
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Canadian
InuitsThe issue of the impact of body burden
versus oral intake on the concentration of
PCB-153 in the milk requires some discus-
sion. Because PCB-153 is a highly lipophilic
compound that is sequestered in adipose tis-
sues, the distribution of lipids into milk is a
function of specific lipid composition of the
milk. Lipids in milk can come from three
sources: a) directly from dietary intake (tri-
acylglycerols originally derived from intestinal
absorption are released from chylomicrons);
b) from maternal adipose stores; and c) from
synthesis by the mammary gland. Dietary
status of the mother inﬂuences the source of
fatty acids. If a mother is in a negative energy
balance, lipids come mostly from adipose
stores. If the maternal diet is low in fat but
provides adequate energy through carbohy-
drates, a greater proportion of fatty acids is
synthesized by the mammary gland. If mater-
nal diet is high in fat, milk fatty acids will
mostly originate from dietary intake (Del
Prado et al. 1999). In the case of a negative
energy balance, because adipose stores are
mostly mobilized, acquired body burden of
PCB-153 will be the most important source
of PCB-153 in milk. In the case of a high-fat
diet, because lipids mostly originate from
diet, dietary intake of PCB-153 will be the
principal source of PCB-153 in milk.
Lactation is metabolically demanding on
the mother, and in most cases, maternal 
adipose stores must be mobilized to provide
enough energy to the newborn. Studies in rats
show that adipose stores are completely
depleted at the end of a lactation cycle (Del
Prado et al. 1999). Therefore, as lipid and thus
PCB-153 body burdens are depleted, dietary
PCB-153 constitutes a greater proportion of
chemical found in milk. However, the appear-
ance of dietary PCB-153 in milk is probably
delayed: Brambilla et al. (2008) showed that
cows fed a diet contaminated with polychlori-
nated dibenzo-p-dioxins (PCDDs) and poly-
chlorinated dibenzofurans (PCDFs) produced
contaminated milk 4 weeks later, whereas con-
tamination tapered off within 75 days after
supplement withdrawal. It is probable that a
meal particularly high in PCB-153 will not
directly result in higher levels in the milk.
We used a number of data sets for valida-
tion of this model (Figure 7): a pseudo-time
course from different mothers of one geo-
graphical location [New York (Schecter et al.
1998)] and Taizhong hospital data; and actual
time courses from individual mothers
[Germany (Abraham et al. 1998); Spain
(Ramos et al. 1997); New York (Schecter et al.
1998)]. Validation data were useful in verify-
ing ranges of values but not necessarily in
identifying trends of PCB-153 concentrations
in milk. There is no clear trend in either the
individual time courses or the population-
based pseudo-time courses. This is not wholly
unexpected in a population-based study
because values are usually mean values and
because such a cohort is subject to great inter-
individual and intraindividual differences.
Similarly, mean values and ranges of PCB-153
milk concentrations in different areas of the
world are of limited use because diet and phys-
iologic attributes differ throughout these areas
and because we have no control over sample
collection times and methods. However, they
are able to validate the ranges and mean values
of our simulation.
The agreement between model predictions
and data in Figure 5 helps to support the level
of complexity employed in this PBPK model.
We condensed the Lee et al. (2007) PBPK
model for PCB-153 in mice because sufﬁcient
data to parameterize an equivalent human
model were unavailable. We also felt that they
were not needed to make predictions at the
global scale. Uncertainties in intake and lacta-
tion rates alone may cause model predictions as
wide as or wider than the range of concentra-
tions reported in the literature. This suggests
that the limiting factor in improving the ﬁdelity
of the PBPK model lies more on understanding
the inputs of the existing model (e.g., intake,
lactation) than in increasing the complexity of
the model by adding tissue compartments.
Although this model is useful in its ability
to describe the distribution, absorption,
metabolism, and elimination of PCB-153 in a
lactating woman, it is also useful in its capacity
to provide an estimate of intake dose given a
certain tissue (or in this case, milk) level of
PCB-153. From our model simulation, the
PCB level found in the milk of the Canadian
Inuits suggests an intake dose almost 50 times
higher than the median value of Akutsu et al.
(2005); that is, 0.294 µg/kg/hr versus 0.0068
µg/kg/hr. This is probably a reflection of a
high rate of consumption of ﬁsh in the Inuit
diet. Similar estimations can be made if other
parameters are known for a certain population
or individual. Additionally, the model can be
expanded to include an infant, which simu-
lates absorption, distribution, metabolism, and
elimination in a nursing child, such as the
approach discussed by Clewell and Gearhart
(2002). Finally, because this model calculated
the partition coefficients for PCB-153 based
on structural properties of the chemical, the
model can be expanded to other PCBs. Using
the formulas described by Parham et al.
(1997), partition coefﬁcients can be calculated
for any PCB.
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Figure 7. Time courses of PCB-153 concentrations in
milk from lactating mothers from various countries.
New York State data are from Schecter et al. (1998);
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value and time of sampling for six lactating women.
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cate time course data for two lactating women. Xs
represent single data points for 20 lactating women
in Taizhong hospital in Taiwan. 
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